Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MAOB | P27338 | 7/20 | 1.00 |
| ▸ | MAOA | P21397 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CASP3 | P42574 | 1/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | APP | P05067 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807601 | 1.00 | MAPT (1.00) | MAPTMAOBMAOACYP2C19CYP2D6 | |
| SCHEMBL30807155 | 1.00 | MAPT (1.00) | MAPTMAOBMAOACYP2C19CYP2D6 | |
| SCHEMBL25202062 | 0.89 | MAOB (1.00) | MAPTMAOBMAOACYP2C19CYP2D6 | |
| SCHEMBL25219836 | 0.87 | MAOB (0.89) | MAPTMAOBMAOACYP2C19CYP2D6 | |
| SCHEMBL25191373 | 0.87 | MAOB (0.89) | MAPTMAOBMAOACYP2C19CYP2D6 | |
| SCHEMBL25233412 | 0.87 | MAOB (0.89) | MAPTMAOBMAOACYP2C19CYP2D6 | |
| SCHEMBL25195966 | 0.87 | MAOB (0.89) | MAPTMAOBMAOACYP2C19CYP2D6 | |
| SCHEMBL7196545 | 0.87 | MAOB (0.80) | MAPTMAOBMAOACYP2C19CYP2D6 | |
| SCHEMBL31234600 | 0.87 | MAOB (0.80) | MAPTMAOBMAOACYP2C19CYP2D6 | |
| SCHEMBL7196541 | 0.87 | MAOB (0.80) | MAPTMAOBMAOACYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2790658-B1 | METHOD OF STRENGTHENING HAIR FIBRES | UNILEVER PLC (GB) | 2017-08-16 | — | — | EP | claimed |
| US-20140366906-A1 | HAIR COLOUR COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2014-12-18 | — | — | US | claimed |
| US-20140335038-A1 | METHOD OF STRENGTHENING HAIR FIBRES | CONOPCO, INC., D/B/A UNILEVER (US) | 2014-11-13 | — | — | US | claimed |
| EP-2790658-A2 | METHOD OF STRENGTHENING HAIR FIBRES | Unilever Plc. (GB) | 2014-10-22 | — | — | EP | claimed |
| EP-2787953-A2 | HAIR COLOUR COMPOSITION | Unilever PLC, a company registered in England and Wales under company no. 41424 (GB) | 2014-10-15 | — | — | EP | claimed |
| WO-2014095318-A2 | METHOD OF PREVENTING HAIR FIBRE DAMAGE | UNILEVER PLC (GB) | 2014-06-26 | — | — | WO | claimed |
| WO-2013087644-A2 | METHOD OF STRENGTHENING HAIR FIBRES | UNILEVER PLC (GB) | 2013-06-20 | — | — | WO | claimed |
| WO-2013083510-A2 | HAIR COLOUR COMPOSITION | UNILEVER PLC (GB) | 2013-06-13 | — | — | WO | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240316118-A1 | ANTIVIRAL NASAL SPRAY FLAVONOIDS?BEE PROPOLIS | MCCAFFREY STEPHEN MARK (AU) | 2024-09-26 | — | — | US | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024035085-A1 | NOVEL COMPOUND, AND COMPOSITION FOR PREVENTING OR TREATING HER2-POSITIVE CANCER, COMPRISING SAME | 이화여자대학교 산학협력단 | 2024-02-15 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007082178-A2 | PROSTAGLANDIN REDUCTASE INHIBITORS | ABGENOMICS CORPORATION (TW) | 2007-07-19 | — | — | WO | disclosed |
| EP-1764363-A2 | SUBSTITUTED ACETOPHENONEDERIVATIVES | Riemser Arzneimittel AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2006-06-29 | — | — | US | disclosed |
| US-5525457-A | Copolymers of unsaturated carboxylic acid, an epoxy-functional monomer, and cinnamoylphenyl group-monomer; high halation preventing effect, involves no sublimation of radiation absorbing components contained therein, possesses excellent heat resistance, dry etching performance, storage stability | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1996-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | MAPT 4566/4885MAOB 1213/4885MAOA 1628/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885MAOB 1004/4885MAOA 1902/4885 |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | LIPC, CYP46A1, HMGCR | MAPT 4801/4885MAOB 2303/4885MAOA 3304/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885MAOB 2435/4885MAOA 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.